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a b s t r a c t
Background: PPARgamma (PPARg) is a nuclear transcription factor involved in the control of lipid and
glucose homeostasis. Two PPARg common polymorphisms, Pro12Ala and 161C > T, have been found to be
associated with cardiovascular disease. In this study, in addition to PPARg coding region, we looked for
genetic variations in promoters and their association with acute coronary syndrome (ACS).
Methods: We studied 202 Italian patients with ACS, and 295 healthy Italian subjects by dHPLC (dena-
turing high-performance liquid chromatography), heteroduplex analysis and direct sequencing or RFLP
(restriction fragment length polymorphism) analysis for screening mutations.
Results: We identified 7 new and 2 already published polymorphisms in PPARg promoters. The C > T93695
(promoter 4) mutation showed significantly different genotype distribution and allele frequency between
controls and ACS patients (p < 0.001); the T allele conferred a protection against ACS at both univariateolymorphism
PARgamma
ranscription factor
(OR: 0.45, 95% CI 0.29–0.69: p < 0.001) and multivariate analysis adjusted for sex, age and traditional
cardiovascular risk factors (OR: 0.44, 95% CI 0.25–0.76: p < 0.005). Moreover, the 161C > T polymorphism
allele frequency (p = 0.03) and genotype distribution (p = 0.015) resulted to be different in ACS group if
compared to healthy controls.
Conclusions: The protective role of 93695C > T polymorphism in PPARg promoter in ACS suggests that
ay afPPARg genetic variants m
. Introduction
Peroxisome proliferator-activated receptor-gamma (PPARg) is a
uclear transcription factor involved in the control of energy, as
ell as in the lipid and glucose homeostasis [1].
The PPARg gene is located at chromosome 3p25 and produces 4
ifferent PPARg mRNAs by alternative splicing and promoter usage:
he presence of 4 different promoters is thought to allow a finer tun-
ng in the control of gene expression. PPARg1, PPARg3, and PPARg4
RNAs encode the same protein [2–4], whereas PPARg2 mRNA
roduct has an additional 30 amino acids (exon B) at the N terminus
5].PPARg1 mRNA is rather ubiquitously expressed, PPARg3 mRNA
s restricted to adipose tissue, colon epithelium, and macrophages,
PARg2 mRNA expression is confined to adipose tissue, whereas the
ocation of PPARg4 mRNA expression has not yet been investigated
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[6]. Much evidence exists indicating that PPARg is an important
determinant of gene expression in the adipocyte differentiation [7],
a key process in the development of obesity, and, in turn, a risk fac-
tor for type 2 diabetes. In addition, PPARg may act directly on local
vasculature in critical aspects of atherogenesis, e.g. interfering with
vascular smooth muscle cells (VSMC) migration and plaque desta-
bilization, reducing the expression of matrix metalloproteinase-9 in
macrophages and VSMC, transforming macrophages in foam cells
via oxidized-low density lipoproteins (ox-LDL) [8–15].
Two common polymorphisms of PPARg coding region have been
widely studied: the Pro12Ala substitution a C > G change in exon
B and 161C > T (Hys477Hys) in exon 6. Other authors found the
Pro12Ala polymorphism associated with type 2 diabetes [16–18],
insulin resistance [19], obesity [20], and cardiovascular diseases
[21], while the T allele of the 161C > T polymorphism has been
shown to be associated with reduced severity of coronary artery
disease (CAD), measured as number of narrowed major coronary
arteries [22].
On the other hand, few studies concerning PPARg promoter poly-
morphisms have been performed: a C > G substitution at position
−681 from exon A2 (promoter 3) has been found to be associated
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23]. Furthermore, an association between PPARg GTGC haplotype
corresponding to the P3-681C > G, P2-689C > T, Pro12Ala, C > G, and
431C > T polymorphisms in this order) and the metabolic syn-
rome in the French population has been reported [24].
However, no definite data regarding the role of genetic variants
n the occurrence of coronary atherosclerosis are available. Thus,
e designed the present study in order to: (1) look for genetic vari-
tions in PPARg promoters between 2 Italian populations, acute
oronary syndrome (ACS) patients and clinically healthy subjects;
2) investigate the possible relationship between the Pro12Ala and
61C > T polymorphisms of PPARg and ACS.
. Materials and methods
.1. Study population
The study population included 202 consecutive Italian patients
143 males and 59 females) recruited between March and Septem-
er 2005 with a diagnosis of ACS and underwent primary
ercutaneous coronary intervention (PCI) at the Catheterization
aboratory of the Heart and Vessels Department of the Azienda
spedaliero-Universitaria Careggi, Florence, Italy. All patients
nderwent coronary angiography performed by the Judkins’
ethod and PCI with bare metal or drug-eluting stent implantation
or de novo stenosis in ≥1 native coronary artery. Coronary vessels
ith at least 75% stenosis were defined as diseased.
Acute myocardial infarction was diagnosed according to the
riteria established by the American College of Cardiology [25].
nstable angina was defined as a history of new-onset, more fre-
uent, more persistent or rest episode of chest pain, without typical
hanges of myocardial enzymes. The subjects were classified as
aving hypertension according to the guidelines of the European
ociety of Hypertension/European Society of Cardiology or if they
eported taking antihypertensive medications, as verified by the
hysician [26]. Diabetic subjects were defined according to the
riteria of the American Diabetes Association or on the basis of
elf-report data (if confirmed by medication or chart review) [27].
yslipidemia was defined according to the Third report of the
ational Cholesterol Education Program or if they reported taking
ntidyslipidemic drugs, as verified by the physician [28]. Body mass
ndex was calculated as weight (kg)/height (m2). A positive family
istory of cardiovascular diseases was defined as the presence of
t least one first-degree relative who had developed a cardiovas-
ular disease before the age of 55 years for men and 65 years for
omen. All patients signed an informed consent; the study com-
lies with the Declaration of Helsinki and was approved by the
ocal ethic committee. All patients received standard therapy that
ncluded aspirin, clopidogrel, low-molecular-weight heparin, intra-
enous nitrates, statins, -blockers, angiotensin converting enzyme
nhibitors, and so forth when appropriate. The control group con-
isted of 295 Italian unrelated subjects recruited from a population
tudy conducted in Florence, Italy, between 2002 and 2004 [29]. A
etailed interview addressed to personal and familial history was
erformed in the frame of a physical examination by expert physi-
ians, in order to identify symptom-free subjects and to exclude
hose who were suspected of having some form of vascular dis-
ase.
All subjects signed an informed consent; the study complies
ith the Declaration of Helsinki and was approved by the local ethic
ommittee..2. Molecular analysis of the PPARg gene
Genomic DNA was isolated from peripheral blood with a QIAmp
lood Kit (QIAGEN, Hilden, Germany). Mutation screening analy-
is of PPARg genomic fragments was performed by amplificationosis 205 (2009) 186–191 187
of 8 fragments covering promoter 2 (Pr2), promoter 3 (Pr3), pro-
moter 4 (Pr4), exon B and exon 6 by using primers and temperatures
described in Supplementary material. The promoter amplified
products were analyzed by electrophoresis on a 2% agarose gel
searching for short insertions/deletions. The denaturing high-
performance liquid chromatography (dHPLC) analysis was carried
out as previously described [30] by using the WAVE DNA Fragment
Analysis System (Transgenomic, Cheshire, UK) after fast denaturing
and slow re-naturing cycle of the amplified fragments.
Sequencing of the heteroduplexes was performed on an ABI310
sequencer by using the BigDye chemistry (Applied Biosystems,
Warrington, Cheshire, UK).
2.3. Genotype typing
Genotyping of the following sequence variation in PPARg gene
was carried out by restriction fragment length polymorphism
(RFLP). Ten microliters of PCR products were digested at 37 ◦C for
the first 5 fragments and at 65 ◦C for the sixth fragment for 6 h with
1 unit of restriction enzyme.
The 25819C > G sequence variation in Pr3 was digested with
MboII which cuts the wild type allele into two fragments
(133 + 195 bp). The 26233T > A sequence variation in Pr3 was
digested with Pdm I restriction enzyme which cuts the wild type
allele into two fragments (321 + 54 bp). The 93695T > C sequence
variation in Pr4 was digested with Sdu I, which cuts the mutated
allele into two fragments (240 + 141 bp). The Pro12Ala variation
in Exon B was digested with Msp I, which cuts the wild type
allele (20 + 217). The 161C > T sequence variation in Exon 6 was
digested with Eco72 I, which cuts the wild type allele (105 + 194).
The 93673T > C sequence variation in Pr4 was digested with Tai I
which cuts the mutated allele into two fragments (215 + 166 bp).
Where genotyping analysis by RFLP was not possible, we detected
homozygous by dHPLC analysis: the amplicons of each subject
(patients and controls) were mixed with the corresponding ampli-
cons of a sequenced wild type, in a 1:1 quantitative ratio before
undergoing a second heteroduplex analysis. Heteroduplexes were
sequenced.
2.4. Statistical analysis
Statistical analysis was performed by using the Statistical Pack-
age of Social Sciences (SPSS, Chicago, IL) software for Windows
(Version 11.5). Data are expressed as median and range. The 2 test
was used to test for proportions and deviations of genotype distri-
bution from Hardy–Weinberg equilibrium, the Fisher’s exact test
was used in the analyses of genotype frequencies where numbers
below five were present. All variations in allele frequencies were
obtained by direct count. The nonparametric Mann–Whitney test
was used for comparisons between single groups. Kruskal–Wallis
test was used to compare the different groups. To assess differ-
ent models at each locus, genotypes at each position were coded
as recessive model (e.g., Pr3 25819 GG vs 25819 CG + CC) and as
dominant model (e.g., Pr3 25819 GG + CG vs CC). The relationship
between the six polymorphisms and ACS was determined by uni-
variate logistic regression analysis. Variables showing, at univariate
analysis, a statistically significant association with ACS were intro-
duced in a multivariate model to evaluate the association with the
disease after adjustment for traditional cardiovascular risk factors.
Odd ratio (OR) with 95% confidence interval (CI) was determined.
p < 0.05 was considered to be statistically significant.3. Results
Demographic characteristics and traditional risk factors for
ACS are described in Table 1. As expected, patients showed a
188 L. Evangelisti et al. / Atheroscler
Table 1






Age (years)* 66 (25–89) 64 (20–89) 0.4
Males, n (%) 143 (70.8) 205 (69.6) 0.8
Females, n (%) 59 (29.2) 90 (30.4) 0.8
Hypertension, n (%) 120 (59.4) 51 (17.2) <0.0001
Dyslipidemia, n (%) 96 (47.5) 60 (20.3) <0.0001
Smoking habit, n (%) 105 (52) 68 (23) <0.0001










































iabetes, n (%) 54 (26.7) 14 (4.7) <0.0001
amily history of CAD, n (%) 56 (27.7) 18 (6.1) <0.0001
* Median (minimum and maximum value).
ignificantly higher prevalence of traditional cardiovascular risk
actors with respect to clinically healthy subjects.
Table 2 shows genotype distributions and allele frequencies
or all the identified PPARg mutations in ACS patients and clin-
cally healthy subjects. All the frequency distributions are in
ardy–Weinberg equilibrium.
In promoter 3 of PPARg4 DNA variants were identified, 2 of them
re novel; in addition 2 new variants were identified in 5′-UTR
untranslated region) of PPARg2 gene. For these mutations no dif-
erence between patients and clinically healthy subjects was found.
In promoter 4 of PPARg, never scanned for variations, 3 vari-
nts were found: the 93695C > T mutation showed a significantly
ifferent distribution between control subjects and ACS patients
genotype distribution: p = 0.03; allele frequency: p = 0.006).
With regard to the common polymorphism 161C > T, T allele
requency (p = 0.03) and genotype distribution (p = 0.015) were sta-
istically different in ACS group with respect to controls. Finally, no
ifferent distribution between ACS patients and clinically healthy
ubjects for Pro12Ala polymorphisms was found.
In order to evaluate if these polymorphisms were significantly
ssociated with ACS, we carried out a logistic regression analysis
hich showed a significant protection of the rare 93695T allele of
he promoter 4 polymorphism (OR: 0.6, 95% CI 0.4–0.9, p = 0.01)
gainst ACS. This result was confirmed even when we adjusted the
nalysis for the traditional cardiovascular risk factors (i.e. gender,
ge, smoking habit, diabetes, dyslipidemia, family history of ACS)
OR: 0.5, 95% CI 0.3–0.9, p = 0.02) (Table 3).
No association for metabolic and lipid profiles according to geno-
ypes of all studied polymorphisms (25819C > G, 26233 T > A, 93673
> C, 93695 C > T, Pro12Ala C > G, 161C > T) was found (Table 4).
Moreover, we sub-grouped our patient population according to
he clinical severity of the disease, i.e. acute myocardial infarction
nd unstable angina, and we observed a statistically significant dif-
erence between the two groups of patients for the two common
olymorphisms 161C > T (0.07 vs 0.22, p = 0.0086) and Pro12Ala
0.06 vs 0.16, p = 0.02), for acute myocardial infarction and unsta-
le angina, respectively, while no differences for the 93695C > T
utation were found.
The two groups of patients did not show significant differences
n terms of demographic characteristics and traditional risk factors
or ACS, apart from gender (data not shown).
. Discussion
Several authors extensively investigated PPARg coding region,
ut few data are available about the regulatory regions, such as the
romoters. In the present study we have identified several poly-
orphisms by carrying out a molecular screening analysis of the
PARg promoters 2, 3 and 4.
Among the variants observed in promoter 4, we identified the
3695C > T substitution; interestingly, this novel polymorphismosis 205 (2009) 186–191
exhibited a significant difference in genotype distribution and allele
frequency between patients and control subjects and showed an
independent protective role against ACS in a logistic regression
model adjusted for traditional cardiovascular risk factors in the
Italian population. Further studies are required to verify the pres-
ence and the association of this polymorphism with ACS in other
populations.
Sequence analysis of the promoter 4 genomic DNA revealed the
existence of putative regulatory elements, some of which (Ap1,
RORE, TATA) were studied by Sundvold and Sigbjørn [4]. Inter-
estingly, the 93695C > T polymorphism is located at a binding
consensus site for the transcription factor Zeste (searching by Tess-
software). Zeste is a DNA binding protein that binds to enhancers
and promoters of a number of developmentally important genes
[31]. So far no Zeste-like proteins have been found in mammals,
thus suggesting that the sequence variation in this binding site may
have a role in modulating transcription of PPARg gene.
The fact that metabolic parameters did not differ between the
93695C/T genotypes may suggest that the 93695C > T or the 161C > T
DNA variation affect the predisposition to ACS via one of the PPARg
actions not involved in lipid and glucose metabolism.
Modulation of PPARg expression in vascular cells (e.g. VSMC,
macrophages, endothelial cells) might influence vascular remod-
elling and inflammatory processes, being critical steps in CAD
development. These effects are mediated in part by the regulation
of transcription factors AP-1, STAT and NF-kB [8–15]. In particu-
lar PPARg activators inhibit proliferation and migration of vascular
cells [14] and leukocyte-endothelial cell interaction [13]. More-
over, PPARg inhibits the synthesis of matrix metalloproteinase
MMP9 and scavenger receptor A in macrophages [11] while pro-
moting monocyte/macrophage differentiation and gene expression
by influencing the uptake of oxidized LDL [8,9].
Further studies on the functional consequences of the
93695C > T polymorphism are required to clarify the role of this
variant in ACS.
Regarding promoter 3, Meirhaeghe et al. [23] described the
25819C > G polymorphism in this regulatory region. In a French
population, the authors found an allele frequency (0.25) signifi-
cantly different (p = 0.03) from the one detected in the Italian group
(Table 2). Moreover, their results showed a correlation between the
presence of the G allele with higher total cholesterol, LDL choles-
terol and body weight. Our findings did not show a similar trend in
the Italian population.
The 26233T > A variant, detected in promoter 3, is already
present in an international database (accession number AY157024).
Two new mutations, 65597T > C and 65600G > T, in 5′-UTR of
PPARg2 with a very low allele frequency (<1%) have been detected;
in particular, the 65597T > C is located at the end of an AP-1 binding
site (nt + 1 from the 3′ end of the recognition sequence). The pres-
ence of both these mutations only in control subjects will require
further investigation on a larger number of subjects to verify if these
variants may play a protective role against ACS development.
Several studies about 161C > T polymorphism have been pub-
lished. A French study [16] reported that in obese subjects 161C > T
polymorphism influences circulating leptin levels. Recently, Chao
et al. [32] observed an association between the 161TT genotype
and premature acute myocardial infarction in Chinese. Therefore,
PPARg seems to be involved in the genesis of ACS and our data
showed that the T allele is statistically more frequent in ACS patients
than in healthy subjects. On the other hand, Wang et al. [22] found
a reduced CAD risk in 161CT heterozygous Australian patients,
although their findings were based only on a selected high-risk
hospital cohort of patients. Moreover, in our CAD patients the
prevalence of T allele resulted to be significantly higher in those
who were affected by angina with respect to those with myocar-
dial infarction. This result suggests a relationship between the
L. Evangelisti et al. / Atherosclerosis 205 (2009) 186–191 189
Table 2
Genotype distribution and allele frequencies of PPARg polymorphisms. (Novel mutations are in grey-shadowed lines.).
*Genotype distribution and §allele frequency.
Table 3
Multivariate logistic regression.
Multivariate analysis OR 95% CI p
Gender (males vs females) 0.5 0.3–1.1 0.9
Age 1.01 0.9–1.026 0.2
Hypertension 6.5 3.9–10.7 <0.0001
Diabetes 7.2 3.3–15.6 <0.0001
Dyslipidemia 4.9 2.9–8.2 <0.0001
Family history of CAD 5.9 2.9–12.1 <0.0001
Smoking habit 3.8 2.3–6.3 <0.0001
PPARg Pr4 93695 CT + TT 0.5 0.3–0.9 0.02
190 L. Evangelisti et al. / Atherosclerosis 205 (2009) 186–191
Table 4












25819 CC (n = 318) 199.5 ± 44.2 55.1 ± 13.7 119.9 ± 86.1 112.7 ± 30.9 0.94 ± 0.28 26.9 ± 3.9
25819 CG (n = 161) 191.3 ± 42.2 56.7 ± 13.3 109.2 ± 55.0 110.3 ± 33.4 0.88 ± 0.15 25.7 ± 3.6
25819 GG (n = 19) 191.9 ± 32.5 49.2 ± 11.4 150.3 ± 94.0 112.2 ± 25.0 0.97 ± 0.23 26.5 ± 4.5
p 0.4 0.1 0.1 0.9 0.7 0.3
26233 TT (n = 318) 199.7 ± 44.1 55.1 ± 13.6 119.8 ± 85.9 112.9 ± 31.1 0.94 ± 0.28 26.9 ± 3.9
26233 TA (n = 162) 191.2 ± 42.2 56.8 ± 13.3 109.4 ± 55.0 110.1 ± 33.2 0.88 ± 0.15 25.7 ± 3.6
26233 AA (n = 17) 189.7 ± 32.6 48.1 ± 10.8 153.7 ± 92.6 109.0 ± 24.7 0.98 ± 0.24 26.8 ± 4.5
p 0.2 0.08 0.3 0.07 0.1 0.8
93673 TT (n = 483) 196.7 ± 43.3 55.2 ± 13.4 118.1 ± 78.9 112.5 ± 31.5 0.92 ± 0.24 26.5 ± 3.8
93673 TC (n = 15) 190.6 ± 38.3 58.3 ± 14.6 106.4 ± 24.6 96.4 ± 29.9 1.00 ± 0.18 27.4 ± 4.4
93673 CC (n = 0) – – – – – –
p 0.8 0.5 0.8 0.2 0.2 0.5
93695 CC (n = 366) 195.7 ± 44.7 54.9 ± 13.5 119.2 ± 84.5 111.2 ± 32.0 0.92 ± 0.24 26.6 ± 3.9
93695 CT (n = 116) 198.7 ± 39.3 56.2 ± 13.8 113.3 ± 55.6 114.6 ± 31.2 0.92 ± 0.23 26.2 ± 3.8
93695 TT (n = 16) 200.5 ± 33.4 57.6 ± 10.2 115.8 ± 44.6 113.6 ± 23.4 0.98 ± 0.33 27.4 ± 3.9
p 0.8 0.6 0.9 0.9 0.7 0.7
P12A CC (n = 427) 197.1 ± 43.6 55.4 ± 13.7 117.1 ± 78.9 112.3 ± 31.7 0.93 ± 0.25 26.7 ± 3.9
P12A CG (n = 68) 193.5 ± 41.4 54.7 ± 12.8 122.0 ± 71.8 110.1 ± 31.7 0.89 ± 0.15 25.6 ± 3.4
P12A GG (n = 3) 181.0 ± 21.2 52.0 ± 11.2 73.0 ± 15.2 114.0 ± 34.2 0.88 ± 0.16 31.1 ± 12.0
p 0.2 0.5 0.9 0.9 0.8 0.6
161 CC (n = 412) 197.1 ± 43.9 55.2 ± 13.7 118.4 ± 80.2 112.5 ± 32.3 0.93 ± 0.26 26.6 ± 3.9




































61 TT (n = 5) 169.7 ± 28.4 55.0 ± 6.8
0.3 0.9
ata are expressed as mean ± SEM.
resence of this polymorphism and the severity of cardiovascular
isease.
As regards the common polymorphism Pro12Ala, Ridker et al.
21] reported that the presence of Ala allele was associated with
reduced incidence of myocardial infarction in North-American
en; in our study no different distribution for Pro12Ala was found
etween ACS patients and controls for both allele frequency and
enotype distribution. These conflicting results might be due to
he different clinical severity of pathology; indeed, by dividing our
atient population in subgroups according to the clinical severity
f disease, the prevalence of Ala allele resulted to be significantly
igher in patients affected by angina with respect to those with
yocardial infarction. On the other hand, our population comprised
higher number of males in the angina group with respect to the
yocardial infarction group. Thus it is likely that the role of these
olymorphisms (C > T161 and Pro12Ala) becomes evident in milder
athological conditions where the traditional cardiovascular risk
actors are weakly present, or in a specific gender, as otherwise
reviously reported [21].
On the other hand, the conflicting results might also be related to
he different genetic background: the population recruited by Rid-
er et al. [21] was predominantly made up by white U.S. males (but
hite may correspond to a pool of subjects with high genetic vari-
bility) and a low percentage of non-Caucasian subjects; moreover,
n our Italian population there are 25% female subjects.
Recent papers did not find any association between Pro12Ala
olymorphism and myocardial infarction [33,34] except for a minor
isk of myocardial infarction in subjects affected by diabetes type
[35] and a higher risk of myocardial infarction in Chinese Han
opulation [36].
We hypothesized that the Pro12Ala polymorphism per se may
ot be sufficient to significantly affect the risk of ACS. Rather, it isikely to play a role by interacting with additional environmental
nd supposedly genetic factors, which may be different in different
opulations.
Wolford et al. [37] reported an association of PPARg variants with
he response to PPARg agonist (troglitazone), suggesting a new role± 71.9 108.5 ± 12.0 0.90 ± 0.16 26.1 ± 3.2
0.8 0.8 0.7
for these variants in PPARg ligand therapy which stresses the impor-
tance of studies searching for new genetic variants for therapeutic
interventions. The identification of mutations acting as modula-
tors of PPARg gene expression may enlighten one aspect of the
complex functional role of this gene and suggest new perspectives
for the PPARg ligand therapy in cardiovascular diseases. However,
the present finding needs to be strengthened by both increasing
samples size and functional studies.
5. Conclusions
We have identified a new PPARg polymorphism (93695C > T)
localized in a regulatory region and demonstrated the protective
role of this polymorphism against ACS.
These results add further weight to the possible role of PPARg
on the occurrence of clinical manifestations of atherosclerotic dis-
eases and stimulate the need for studies addressed to investigate
the association of this factor with different clinical manifestations
of the coronary artery disease as well as with different localizations
of the atherothrombotic process.
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